Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286681 | 0.94 | HSD11B1 (0.35) | HSD11B1HCRTR1HCRTR2 | |
| SCHEMBL13705267 | 0.90 | HCRTR1 (0.35) | GPR119GABRA5HPGDSHCRTR1HCRTR2 | |
| SCHEMBL13705262 | 0.90 | HPGDS (0.33) | GPR119GABRA5HPGDSHSD11B1USP30 | |
| SCHEMBL13705256 | 0.88 | EGFR (0.35) | GPR119HPGDSHSD11B1USP30EGFR | |
| SCHEMBL13705261 | 0.87 | HPGDS (0.34) | HPGDSUSP30PRMT5HCRTR1HCRTR2 | |
| SCHEMBL13705254 | 0.87 | HPGDS (0.36) | GPR119HPGDSHSD11B1USP30PRMT5 | |
| Hydrochloric Acid SCHEMBL4752479 | 0.86 | USP19 (0.35) | HSD11B1HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL4289682 | 0.86 | USP19 (0.35) | HSD11B1HCRTR1HCRTR2 | |
| SCHEMBL13705306 | 0.86 | HPGDS (0.35) | HPGDSHSD11B1USP30PRMT5HCRTR1 | |
| SCHEMBL13705263 | 0.85 | IDH1 (0.36) | HPGDSUSP30PRMT5HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GPR119 310/4885GABRA5 1948/4885HPGDS 1198/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GPR119 310/4885GABRA5 1948/4885HPGDS 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.